Flumazenil

Flumazenil

• CAS Number: 78755-81-4
• UNSPSC Description: Flumazenil is a competitive GABAA receptor antagonist, used in the treatment of benzodiazepine overdoses.
• Target Antigen: GABA Receptor
• Type: Reference compound
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/Flumazenil.html
• Purity: 99.97
• Solubility: DMSO : 20 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C(C1=C2CN(C(C3=CC(F)=CC=C3N2C=N1)=O)C)OCC
• Molecular Weight: 303.29
• References & Citations: [1]Hoffman EJ, et al. Flumazenil: a benzodiazepine antagonist. Clin Pharm. 1993 Sep;12(9):641-56; quiz 699-701|[2]Belzung C, et al. Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice. Psychopharmacology (Berl). 2000 Jan;148(1):24-32.|[3]Fernandez-Guasti A, et al. Flumazenil blocks the anxiolytic action of allopregnanolone. Eur J Pharmacol. 1995 Jul 25;281(1):113-5.|[4]Loscher W, et al. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil. Br J Pharmacol. 1994 Dec;113(4):1349-57.|[5]Moy SS, et al. Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology (Berl). 1997 Jun;131(4):354-60.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched